Decipher by Veracyte @Decipher_VCYT Twitter profile

Last Seen Profiles

@Dr_YasminRashid

@mikuhourly

@Jtouray78

@hearnimator

@goosebreeder

@bi_de_festa

@Melika192827

@LuquitaRodrigue

@na_girlsbb

@DianaIo51632489

@prexerp

@HyogaOni

@Eff3rvescence

@farmingtonfast

@starwars

@nao313730772851

@TiffanyTarpley

@kscitymonarchs

@DrSanMukherji

@yslbeauty

@Agness_Cuck

@FrieBonacc

@p_minamikawa

@PatriotSkyrific

@caps_ko

@FNUAthletics

@mee_tunde

@mmeow_mee

@skylarromines

@ambarfrancoh

@HaroonHakimi1

@AsadRehman915

@questionmarkliv

@_irinamailen

@CYXuAxfGlfFzZCT

@V20Group

Decipher by Veracyte

@Decipher_VCYT

3 years

Are you attending #ASTRO2021 this year? Meet with @Veracyte ’s Elai Davicioni, PhD to talk about prostate cancer genomics!

1

20

118

Decipher by Veracyte

@Decipher_VCYT

2 years

Check out @UroToday 's video featuring leading #ProstateCancer physicians discussing an analysis of the phase 3 RTOG 0126 study that validates the performance of @Veracyte 's #Decipher Prostate Genomic Classifier as a biomarker for men w/ #intermediate -risk disease.

Validation of Performance of the Decipher Biopsy Genomic Classifier

urotoday.com

1

24

108

Decipher by Veracyte

@Decipher_VCYT

4 years

Decipher Prostate Biopsy is the first genomic test to receive Medicare coverage for men diagnosed with favorable and unfavorable intermediate-risk prostate cancer! #Decipher #ProstateCancer #biomarkers #Medicare

0

15

34

Decipher by Veracyte

@Decipher_VCYT

4 years

Decipher predicts OS and is the 1st genomic classifier validated in a Phase III RCT in prostate cancer. Decipher identified high-risk men likely to benefit from the addition of hormones to SRT. @DrSpratticus gives his view on this important development.

Decipher in RTOG 9601: Daniel Spratt, MD

Daniel Spratt, MD, Professor of Radiation Oncology at University of Michigan discusses the results of Decipher in the RTOG 960 trial of salvage radiation wit...

www.youtube.com

0

9

26

Decipher by Veracyte

@Decipher_VCYT

2 years

Not all newly-diagnosed, clinically high-risk #ProstateCancer patients are the same. Check out this paper that discusses the definition and validation of a "favorable" high-risk group.

Definition and Validation of “Favorable High-Risk Prostate Cancer”: Implications for Personalizing...

To define and validate a classification of favorable high-risk prostate cancer that could be used to personalize therapy, given that consensus guidelines recommend similar treatments for all radiat...

www.redjournal.org

0

5

23

Decipher by Veracyte

@Decipher_VCYT

3 years

Hear from the experts! 📢 @UCSFUrology urologist @dr_coops , @JEFFUrology radiation oncologist @RobertDen6 and @miami_urology urologist @sanojpunnen discuss the increasing importance of biomarkers in determining treatment for prostate cancer patients.

Matthew Cooperberg, MD, MPH on Biomarkers in Prostate Cancer Active...

Matthew Cooperberg, MD, MPH from the University of California San Francisco presents his perspective on the use of biomarkers in the prostate cancer active s...

www.youtube.com

0

11

16

Decipher by Veracyte

@Decipher_VCYT

3 years

A new @urotoday video features @DrSpratticus and @ashleyrossmdphd discussing an independent systematic review of #Decipher in 42 studies w/ 30k+ patients that revealed the test to be independently prognostic for OS, metastasis, and other endpoints. Watch:

0

13

16

Decipher by Veracyte

@Decipher_VCYT

4 years

Great prospective study by @RobertDen6 and colleagues defining the clinical utility and benefit of #Decipher in men following prostatectomy further validating the previous PRO-IMPACT trial results

Prospective study to define the clinical utility and benefit of Decipher testing in men following...

Prostate Cancer and Prostatic Diseases - Prospective study to define the clinical utility and benefit of Decipher testing in men following prostatectomy

www.nature.com

0

8

15

Decipher by Veracyte

@Decipher_VCYT

1 year

A new study from @EurUrolOpen of post-biopsy prostate cancer patients showed tumor volume was not associated with aggressive tumor biology (Decipher score) in GG1 disease, suggesting that in these patients, tumor volume may not be informative for active surveillance decisions.

Prostate Cancer Tumor Volume and Genomic Risk

sciencedirect.com

0

8

15

Decipher by Veracyte

@Decipher_VCYT

8 years

GenomeDX Launches Decipher Biopsy Test @DecipherTest

0

4

14

Decipher by Veracyte

@Decipher_VCYT

4 years

As featured in the @urotoday commentary with @AndreaNecchi , #Decipher identifies #MIBC patients with a specific molecular subtype that are most likely to benefit from neoadjuvant immunotherapy with @Merck #KEYTRUDA

0

6

14

Decipher by Veracyte

@Decipher_VCYT

3 years

#Decipher analysis of the RCT SPARTAN, a trial of apalutamide in #prostatecancer (nmCRPC) patients, found that the Decipher test and #DecipherGRID basal-luminal subtypes may be biomarkers of response to apalutamide+ADT. @Veracyte @decipher_bio @felixfengmd

Molecular Subtypes Associated With Differential Outcome to Apalutamide Identified in Prostate Cancer

This prognostic study of molecular subtypes examines the addition of apalutamide to androgen deprivation therapy in men with nonmetastatic castration-resistant prostate cancer.

jamanetwork.com

1

9

13

Decipher by Veracyte

@Decipher_VCYT

3 years

Get a fresh perspective on genomics in the post-prostatectomy setting! Watch Part 1 of @UroToday ’s 3-part series featuring Dr. Spratt, Dr. Ross, and Dr. Dal Pra discussing new data from SAKK 09/10 and RTOG 96-01, and the new #Decipher Prostate RP report!

Personalized Hormone Therapy with Post-Operative Radiation Therapy and Validation of the Decipher...

In this UroToday presentation Daniel Spratt, MD, and Alan Dal Pra, MD, share results from recent clinical trials that highlight the timing and patient selection for the personalization of hormone...

www.urotoday.com

0

7

13

Decipher by Veracyte

@Decipher_VCYT

3 years

Listen to part 2 of @UroToday ’s 3-part series! @DrSpratticus discusses RTOG 9601 & GETUG-AFU on the addition of hormone therapy to RT in post-RP patients with a rising PSA & how he utilizes the @Veracyte Decipher prostate test for treatment decisions

0

11

13

Decipher by Veracyte

@Decipher_VCYT

4 years

Treatment decisions made using Decipher after radical prostatectomy significantly improve prostate cancer patient outcomes #Decipher #prostatecancer #biomarker #genomicclassifier

0

7

12

Decipher by Veracyte

@Decipher_VCYT

4 years

New Study In African-American Men from the @vadurham and @SFreedlandMD Highlights the Unprecedented Accuracy of Decipher in Predicting Metastasis and PCSM. #ProstateCancer #Genomics #biomarker #Decipher

Validation of a genomic classifier for prediction of metastasis and prostate cancer-specific...

Prostate Cancer and Prostatic Diseases - Validation of a genomic classifier for prediction of metastasis and prostate cancer-specific mortality in African-American men following radical...

www.nature.com

0

3

12

Decipher by Veracyte

@Decipher_VCYT

4 years

Yet another paper highlighting the clinical utility of Decipher in men undergoing Radical Prostatectomy: the PRO-IMPACT trial

0

6

12

Decipher by Veracyte

@Decipher_VCYT

2 years

ICYMI: Data presented earlier this year at ASCO GU further validated the clinical utility of Decipher Prostate for helping to guide therapy in men with intermediate-risk prostate cancer. Learn more here:

Learn How Veracyte's Decipher GC Can Help Men with Prostate Cancer

decipherbio.com

0

4

11

Decipher by Veracyte

@Decipher_VCYT

4 years

🎄Happy Holidays from the Decipher Vancouver Team 🎄 #Decipher #happyholidays2019 #vancouver

0

11

Decipher by Veracyte

@Decipher_VCYT

3 years

It's exciting to see the results presented at #ASTRO2021 that show the Decipher Prostate test can play a role in shared decision-making for patients with clinically high-risk #ProstateCancer .

Veracyte, Inc.

@Veracyte

3 years

Data shared today at #ASTRO2021 validate the prognostic value of the Veracyte #Decipher Prostate genomic test in an analysis of biopsy samples from three Phase 3, randomized trials of men w/ high-risk #ProstateCancer . Read more:

0

14

20

0

4

11

Decipher by Veracyte

@Decipher_VCYT

3 years

This novel study found significant differences in gene expression between samples from bladder cancer tumors before and after treatment with pembrolizumab, an immunotherapy drug. Important implications for biomarker-based adjuvant therapy selection.

Andrea Necchi

@AndreaNecchi

3 years

I am pleased to share our last platinum priority paper from collaborative work: Molecular Characterization of Residual Bladder Cancer after Neoadj Pembrolizumab @ewanagibb @JoepJdeJong @pcvblack @Roland3097 @DanieleRaggi83 @LauraLmar89 #PURE01 @EUplatinum

7

33

115

0

6

11

Decipher by Veracyte

@Decipher_VCYT

2 years

#ICYMI : New data exploring @Veracyte 's #Decipher Genomic Classifiers will be featured in 6 abstracts at this year's ASCO #GU22 meeting.Check out the presentations Feb. 17-19 and then come by Booth 54 to learn more!

Veracyte Announces New Data to be Presented at ASCO #GU22

veracyte.com

0

8

10

Decipher by Veracyte

@Decipher_VCYT

3 years

Did you see? The @Veracyte Decipher Prostate RP genomic classifier is uniquely recommended in the 2022 National Comprehensive Cancer Network® Clinical Practice Guidelines for Oncology. Read more here:

0

11

10

Decipher by Veracyte

@Decipher_VCYT

11 months

ICYMI: Results from an analysis of the Phase 3 RCT NRG/RTOG 0521 suggest patients with high-risk localized prostate cancer classified as luminal proliferating (LP) subtype derive greater benefit from adding docetaxel to RT and ADT than those with non-LP subtypes. #ASCO23 #ASCO

ICYMI: New data from #ASCO23

asco.org

0

7

10

Decipher by Veracyte

@Decipher_VCYT

5 months

We will be attending the Society of Urologic Oncology meeting it will be taking place on November 28th - December 1st 2023 in Washington, DC! Visit our booth & learn how @Veracyte 's Decipher Prostate GC can help men living with #ProstateCancer

0

5

11

Decipher by Veracyte

@Decipher_VCYT

5 years

Decipher in the news from @GenomeMedicine , where our whole transcriptome assay and RNA-seq data from #TCGA were used to identify a group of luminal MIBC patients with favorable prognosis!

Genome Medicine

@GenomeMedicine

5 years

New from @GenomeMedicine : Can #lncRNA profiling inform cancer #precisionmedicine ? @JoepJdeJong , @ewanagibb , @joostboormans , and colleagues use this method to identify a subgroup of bladder cancer patients with a favorable prognosis.

0

6

9

0

4

9

Decipher by Veracyte

@Decipher_VCYT

3 years

Thanks @FierceBiotech for highlighting the acquisition agreement and @freshbrewedtech for amplifying. We're proud to be combining with @Veracyte to advance our platform of genomic classifiers for use in urologic cancers. ICYMI:

Fresh Brewed Tech - SD Tech News

@freshbrewedtech

3 years

In a $600M deal, @Veracyte will acquire San Diego-based @decipher_bio . The combined company's diagnostics will reach 7 of the 10 most common tumor types affecting over 1M new patients per year. | Via @FierceBiotech @ConorHale | #SDTechos

0

4

0

5

9

Decipher by Veracyte

@Decipher_VCYT

4 years

Why Decipher? - Broadly validated across the prostate cancer spectrum (over 140 papers) - Captures the expression of over 46,000 genes for every patient sample - Data, data, data!

Paul Sargos

@PaulSargos

4 years

@felixfengmd open the 2019 #GUROC meeting. Decipher reclassify 67% of #ProstateCancer patients for metastasis risk. Prospective data to validate, in the future, @NRGonc #nrg009 trial leaded by @DrPaulNguyen . Now, #nrg006 study leaded by @DrSpratticus is ongoing.

0

9

16

0

4

9

Decipher by Veracyte

@Decipher_VCYT

4 years

NEWS: Decipher Biosciences Achieves Major Medicare Milestone with Expansion in Coverage for Decipher Prostate Genomic Testing

Decipher Biosciences Achieves Major Medicare Milestone with Expansion in Coverage for Decipher...

/PRNewswire/ -- Decipher Biosciences, a commercial-stage precision oncology company committed to improving patient care, initially focused on urologic cancers,...

www.prnewswire.com

0

11

9

Decipher by Veracyte

@Decipher_VCYT

3 years

Are you attending #ASTRO2021 this year? Meet with Elai Davicioni, PhD to talk about @Veracyte ’s Decipher Prostate test!

0

5

9

Decipher by Veracyte

@Decipher_VCYT

3 years

Decipher is now available for ALL patients with localized prostate cancer!

0

6

9

Decipher by Veracyte

@Decipher_VCYT

3 years

Check out this @UroToday recording featuring Dr. Alicia Morgans and Dr. Kosj Yamoah discussing #Decipher #Prostate testing for African American men in the VANDAAM clinical trial!

Validating the Genomic Classifier to Identify Patients With a High Risk of Metastasis Among African...

When we think about prostate cancer health disparities, particularly there are two main areas of importance, understanding what the effects are and also figuring out what the implementation strateg...

www.urotoday.com

0

3

8

Decipher by Veracyte

@Decipher_VCYT

2 years

Not all prostate cancer should be treated the same. Veracyte's Decipher Genomic Classifier can provide insight into a patient's risk of metastasis, helping to inform treatment decisions.

1

5

8

Decipher by Veracyte

@Decipher_VCYT

3 years

Check out this discussion for additional insight into a comprehensive review of the evidence for Decipher's clinical utility. The analysis took into account more than 40 studies and 30,000+ patients. #decipher #genomics #prostatecancer

UroToday.com

@urotoday

3 years

A systematic review of the Decipher® genomic classifier in #ProstateCancer . @ashleyrossmdphd is joined by @DrSpratticus to discuss a recent @Uroweb publication with substantial evidence to support clinical use. #WatchNow on UroToday > @decipher_bio

0

3

13

0

5

8

Decipher by Veracyte

@Decipher_VCYT

8 months

New data show the ability of a novel gene expression signature to classify #prostatecancer into molecular subtypes that may inform treatment response. The biomarker, derived using @Veracyte 's #Decipher GRID database, could help further prostate cancer treatment personalization.

A novel prostate cancer subtyping classifier based on luminal and basa

wiley.com

0

7

8

Decipher by Veracyte

@Decipher_VCYT

2 years

ASCO #GU22 starts tomorrow! Stop by booth #54 any time Feb 17-19 to learn how @Veracyte 's #Decipher Prostate Genomic Classifier can help clarify the aggressiveness of #ProstateCancer & support personalized therapy decisions. Click to view virtual sessions:

Explore the Virtual Sessions for ASCO #GU22

asco.org

0

4

8

Decipher by Veracyte

@Decipher_VCYT

3 years

Decipher's new Prostate Biopsy test report provides more genomic data, a patient-friendly illustration of risk, relevant clinical findings & other updates designed to make a difference for physicians and their patients. Explore it here: #MotivationMonday

0

4

8

Decipher by Veracyte

@Decipher_VCYT

2 years

We are at the South Central Section AUA Annual Meeting in Coronado, CA happening from September 7-10! Visit our booth to learn how Veracyte, Inc.'s #Decipher Prostate Genomic Classifier can impact treatment planning for men living with #ProstateCancer .

0

2

8

Decipher by Veracyte

@Decipher_VCYT

3 years

Visit us at our #AUA2021 virtual booth! Learn about @Veracyte 's new Decipher Prostate RP Test Report and check out the latest @Urotoday videos featuring Decipher Prostate. #prostatecancer #PCAM

0

4

7

Decipher by Veracyte

@Decipher_VCYT

3 years

African American men are at an increased risk for #ProstateCancer . Early detection improves outcomes. Click here to learn about screening options: #PCAM

African American Disparities In Prostate Cancer

Dr. Kosj Yamoah, MD, PhD of the Moffitt Cancer Center discusses African American disparities in prostate cancer, what work is being done to remove dismantle ...

www.youtube.com

0

2

7

Decipher by Veracyte

@Decipher_VCYT

7 years

GenomeDx Announces Research Collaboration with Astellas to Identify Genomic Drivers of Patient Response to XTANDI®:

0

4

6

Decipher by Veracyte

@Decipher_VCYT

2 years

#Decipher Prostate is an integral biomarker in the NRG Oncology prospective randomized trial (GUIDANCE, GU010) for unfavorable intermediate-risk prostate cancer patients who are randomized to treatment based on their Decipher score. Learn more about this study here:

Learn more about the NRG-GU010 study

nrgoncology.org

0

2

7

Decipher by Veracyte

@Decipher_VCYT

2 years

We will be at the Western Section of the AUA meeting! Stop by our booth on October 30th - November 4th at the Grand Hyatt Kauai, Hawaii to learn about how @Veracyte 's #Decipher Prostate Genomic Classifier can personalize treatment planning for men living with #ProstateCancer .

0

3

6

Decipher by Veracyte

@Decipher_VCYT

1 year

Veracyte's Decipher team is in Chicago, exhibiting at the American Urological Associations 2023 ( #AUA23 ) meeting taking place April 28 - May 1! If you're attending, visit booth #637 to hear about some of our latest research efforts to help patients with #ProstateCancer .

0

5

7

Decipher by Veracyte

@Decipher_VCYT

7 years

GenomeDx’s Decipher Biopsy Demonstrates Ability to Predict Metastasis After Radiation and ADT:

0

5

7

Decipher by Veracyte

@Decipher_VCYT

4 years

Check out the new Decipher Newsletter featuring an interview with Dr. Mark J Fallen, partner with Minnesota Urology, on his experience utilizing Decipher Prostate! #prostatecancer #urology #genomics #biomarker #Decipher

0

3

7

Decipher by Veracyte

@Decipher_VCYT

4 years

Presented at ASCO #GU20 by @felixfengmd , new study of the phase III RTOG 9601 clinical trial highlights the ability of the #Decipher Genomic Classifier to identify #prostatecancer patients likely to benefit from hormonal therapy in addition to SRT.

Decipher Prostate RP Identifies Patients Likely to Benefit from Hormonal Therapy in Men with...

/PRNewswire/ -- Decipher Biosciences, a commercial-stage precision oncology company committed to improving patient care, initially focused on urologic cancers,...

www.prnewswire.com

0

3

7

Decipher by Veracyte

@Decipher_VCYT

1 year

We're kicking off our #EmployeeSpotlight series with one of our talented Customer Experience Managers, Tai Ngo. We want to thank Tai for going above and beyond for our customers and patients in NY, NJ, MI, and MN. Like and comment to join us in our appreciation of Tai!

0

7

Decipher by Veracyte

@Decipher_VCYT

4 years

Join us for a free webinar next Wednesday, July 22! Register here:

0

9

7

Decipher by Veracyte

@Decipher_VCYT

2 years

A new analysis of the phase 3 trial RTOG 0126 shared today at ASCO #GU22 suggests that @Veracyte 's #Decipher Prostate Biopsy test can help physicians tailor treatment for men diagnosed w/ intermediate-risk #ProstateCancer .

NEW DATA VALIDATE CLINICAL UTILITY OF VERACYTE’S DECIPHER PROSTATE

veracyte.com

0

5

7

Decipher by Veracyte

@Decipher_VCYT

2 years

The @Veracyte #Decipher Prostate RP Genomic Classifier is recommended in the 2022 NCCN Guidelines. Learn more here:

0

6

7

Decipher by Veracyte

@Decipher_VCYT

4 months

ICYMI: Data from a post-hoc analysis of the phase 3 RCT RTOG 0126 trial was published in @IJROBP and further validates the clinical utility of @Veracyte 's #Decipher Prostate in guiding patient management in the definitive radiotherapy setting. Read here:

Genomic Classifier Performance in Intermediate-Risk Prostate Cancer: Results From NRG Oncology/RTOG...

Intermediate-risk prostate cancer is a heterogeneous disease state with diverse treatment options. The 22-gene Decipher genomic classifier (GC) retrospectively has shown to improve risk stratificat...

www.redjournal.org

0

4

7

Decipher by Veracyte

@Decipher_VCYT

6 years

GenomeDx Announces Medicare Draft Local Coverage Determination (LCD) for Decipher Prostate Biopsy...

/PRNewswire/ -- GenomeDx Biosciences, a leader in the field of urologic cancer genomics, today announced that Palmetto GBA, a Medicare Administrative...

www.prnewswire.com

0

4

6

Decipher by Veracyte

@Decipher_VCYT

2 years

Performance of @Veracyte 's #Decipher Prostate in a post-hoc analysis of the Phase 3 RCT, STAMPEDE Arm G to be featured in a plenary session at #ESMO22 on Sept 11 at 8:40 am CEST GMT+2. This data validates Decipher in advanced prostate cancer patients receiving ADT +/- abiraterone

Decipher in STAMPEDE Arm G

esmo.org

0

4

7

Decipher by Veracyte

@Decipher_VCYT

2 years

ICYMI: New data from a post-hoc analysis of the STAMPEDE trial presented at #ESMO22 evaluated the clinical performance of the Decipher Prostate test in men with high-risk and metastatic prostate cancer being treated with ADT +/- abiraterone acetate and prednisolone.

Veracyte's Decipher Prostate at ESMO

decipherbio.com

0

4

7

Decipher by Veracyte

@Decipher_VCYT

2 years

Revealing the underlying biology of a patient's prostate cancer tumor can help determine who has less aggressive disease and may experience favorable outcomes with deintensified therapy. Check out @Veracyte 's new #Decipher Prostate Biopsy Report:

0

5

7

Decipher by Veracyte

@Decipher_VCYT

4 years

Behind the scenes #Decipher interview with @anis_a_hamid on his #GU20 presentation highlighting the predictive nature of a Decipher GRID signature for the benefit from chemotherapy in mHSPC as part of the #CHAARTED phase III trial. @DanaFarberNews

0

3

7

Decipher by Veracyte

@Decipher_VCYT

1 year

Decipher Prostate, Bladder, & GRID will be featured in 6 abstracts & 1 general session at ASCO GU 2023! Visit the "Advanced Prostate Cancer: New Targets, New Drugs, New Victories" session today at 10am to hear takeaways of an analysis of #DecipherProstate in STAMPEDE Arm G. #GU23

Check out the abstracts and session featuring Decipher Prostate

asco.org

0

4

6

Decipher by Veracyte

@Decipher_VCYT

7 years

GenomeDx’s @DecipherTest to be Featured in Multiple Presentations at #ASTRO17 :

0

4

Decipher by Veracyte

@Decipher_VCYT

4 years

Decipher now accepts all intermediate risk biopsy samples (3+4 and 4+3)! #Decipher #ProstateCancer #biomarkers #Genomics #Medicare

0

3

6

Decipher by Veracyte

@Decipher_VCYT

9 years

#bladdercancer gets a little boost from #AUA15 (via @healthhashtags ) http://t.co/OpHEwWl5oC

0

9

6

Decipher by Veracyte

@Decipher_VCYT

1 year

A study published in @EurUrolOpen found that tumor volume was not indicative of aggressive tumor biology (Decipher score) in GG1 #ProstateCancer patients post-biopsy, suggesting that factors other than tumor volume may need to be considered in active surveillance decisions.

Prostate Cancer Tumor Volume and Genomic Risk

sciencedirect.com

0

5

6

Decipher by Veracyte

@Decipher_VCYT

2 years

We're excited to participate in the #ASTRO2022 Conference in San Antonio, TX! We invite you to visit us at booth #3803 from October 23-26 to connect with our team and learn about how Veracyte is working to improve outcomes for men living with #ProstateCancer .

0

2

6

Decipher by Veracyte

@Decipher_VCYT

7 years

GenomeDx Announces Initiation by MUSIC of Prospective Study of Decipher:

0

5

Decipher by Veracyte

@Decipher_VCYT

4 years

Decipher Bladder identifies aggressive neuroendocrine-like disease in MIBC #bladdercancer #Decipher #biomarkers #genomictesting #wholetranscriptome

Ewan Gibb

@ewanagibb

4 years

Validation of a genomic classifier for identifying aggressive NE-like disease in muscle-invasive bladder cancer. #bladdercancer @PGrivasMDPhD @jose_bdc @pcvblack @decipher_bio

1

14

31

0

2

6

Decipher by Veracyte

@Decipher_VCYT

11 months

ICYMI: A UroToday video examines recent data on @Veracyte 's #Decipher Prostate test in men with favorable-risk #ProstateCancer who are undergoing active surveillance or watchful waiting in the SEER registry and other real-world datasets. Watch here!

UroToday.com

@urotoday

1 year

Risk assessment in localized #ProstateCancer - Insights from real-world data and SEER registry. @jimhumd @WeillCornell joins @ashleyrossmdphd @NM_Urology to discuss the use of genomic classifiers in the mgmt of localized PCa on UroToday > @Decipher_VCYT

0

2

17

0

4

5

Decipher by Veracyte

@Decipher_VCYT

2 years

#MensHealthMonth is about bringing awareness to health issues affecting men, including #ProstateCancer . @Veracyte 's Decipher Prostate test is here to help those diagnosed with prostate cancer learn more about their tumor biology. Learn more here:

Learn About How Veracyte's Decipher GC Can Help Men Living With

decipherbio.com

0

2

6

Decipher by Veracyte

@Decipher_VCYT

2 years

There are various treatment options for intermediate-risk #ProstateCancer . Knowing more about the underlying biology of a patient's tumor with @Veracyte 's #Decipher Prostate test can help personalize therapy, bringing clarity and confidence to your treatment decisions.

Learn About How Veracyte's Decipher GC Can Help Men With Intermediate

decipherbio.com

0

3

6

Decipher by Veracyte

@Decipher_VCYT

3 years

More exciting data on Veracyte's #Decipher Prostate test presented at #ASTRO2021 show that the Decipher Prostate test can help in managing patients with biochemically recurrent #ProstateCancer Post-RP.

Veracyte, Inc.

@Veracyte

3 years

Data from a phase 3 trial shared today at #ASTRO2021 suggest Veracyte's #Decipher Prostate genomic classifier can help physicians tailor treatment for men w/ #ProstateCancer who are experiencing disease progression after surgery. Read more:

0

4

9

0

3

6

Decipher by Veracyte

@Decipher_VCYT

4 years

Sign up for our webinar with @jmmrad !

1

9

6

Decipher by Veracyte

@Decipher_VCYT

4 years

NEWS: eviCore Clinical Guidelines Incorporate Decipher Prostate into New Medical Necessity Criteria for Prostate Cancer Patients

eviCore Clinical Guidelines Incorporate Decipher Prostate into New Medical Necessity Criteria for...

/PRNewswire/ -- Decipher Biosciences, a commercial-stage precision oncology company committed to improving patient care, initially focused on urologic cancers,...

www.prnewswire.com

0

4

6

Decipher by Veracyte

@Decipher_VCYT

6 years

GenomeDx Biosciences Announces Research Collaboration with Janssen Pharmaceuticals to Evaluate the...

/PRNewswire/ -- GenomeDx Biosciences, a leader in the field of urologic cancer genomics, today announced a research collaboration with Janssen Pharmaceuticals....

www.prnewswire.com

1

0

6

Decipher by Veracyte

@Decipher_VCYT

2 years

Attending #ASTRO2022 ? Be sure to stop by the Post-Prostatectomy Radiotherapy session today at 3pm CDT in room 214, where data will be presented on the performance of @Veracyte 's #Decipher GRID signature, PORTOS, in the Phase 3 RCT, SAKK 09/10.

0

2

5

Decipher by Veracyte

@Decipher_VCYT

7 months

ICYMI: New data from a post-hoc analysis of the phase 3 RCT RTOG 0126 trial was published in @IJROBP and further validates the clinical utility of @Veracyte 's #Decipher Prostate test in guiding patient management in the definitive radiotherapy setting. Read here:

ICYMI: New data alert from The International Journal of Radiation Onco

redjournal.org

0

5

6

Decipher by Veracyte

@Decipher_VCYT

1 year

@Veracyte ’s Decipher team at the 2023 ASCO Genitourinary Cancers Symposium last week. Thank you to those who stopped by to discuss the latest #Decipher data! #GU23 @ASCO

0

1

5

Decipher by Veracyte

@Decipher_VCYT

5 years

At ASTRO? Join us for dinner with @RobertDen6 ! Monday, September 16, 2019 at 6:30 PM at Prime & Provisions. RSVP by texting 763.245.0620

0

3

6

Decipher by Veracyte

@Decipher_VCYT

1 year

This month's #EmployeeSpotlight goes to Katie Nguyen. She monitors and creates material needed to run #Decipher testing, analyzes and presents the lab's quality metrics, & helps everyone stay on top of their paperwork. Like and share to show your appreciation of Katie!

0

6

Decipher by Veracyte

@Decipher_VCYT

10 months

ICYMI: New data from a post-hoc analysis of the phase 3 RCT RTOG 0126 trial was published in @IJROBP & further validates the clinical utility of @Veracyte 's #Decipher Prostate in guiding patient management in the definitive radiotherapy setting. Read here:

0

3

6

Decipher by Veracyte

@Decipher_VCYT

3 years

Hot off the presses from @JAMAOnc : Decipher validates as an independent predictor of overall survival in RTOG 96-01, a Phase 3 RCT - a significant milestone in the development of evidence for the test. #GU21

JAMA Oncology

@JAMAOnc

3 years

Ancillary study of men w #ProstateCancer randomized to placebo vs hormone therapy in NRG/RTOG 9601 clinical trial of salvage radiation, Decipher genomic classifier stratifies men at risk for mets, cancer-specific mortality, & overall surv #PCSM

0

6

9

0

5

6

Decipher by Veracyte

@Decipher_VCYT

4 years

Exciting news from Decipher and @ChrisSweens1 at @DanaFarber ! Decipher GRID signature predicts benefit from chemotherapy in mHSPC as part of the CHAARTED phase III clinical trial. @DanaFarberNews #prostatecancer #GRID #biomarker #genomics #mHSPC

Decipher GRID Signature Predicts Benefit from Chemotherapy in Men Diagnosed with Metastatic...

/PRNewswire/ -- Decipher Biosciences, a commercial-stage precision oncology company committed to improving patient care, initially focused on urologic cancers,...

www.prnewswire.com

1

4

6

Decipher by Veracyte

@Decipher_VCYT

5 months

We are proud to announce that @Veracyte 's #Decipher Prostate testing will be featured in seven posters at the 2023 Society of Urologic Oncology meeting. If you are here, stop by our booth to learn more about #DecipherProstate . #ProstateCancer #SUO23 @UroOnc

0

4

6

Decipher by Veracyte

@Decipher_VCYT

1 year

ICYMI: This video from @UroToday features experts in #prostate cancer management as they discuss the use of Veracyte's #Decipher Prostate test in informing treatment decisions for patients post-biopsy. Check it out!

UroToday.com

@urotoday

2 years

The use of the #Decipher biopsy genomic risk assessment test prior to prostatectomy. @ashleyrossmdphd @NM_Urology joins @CaPsurvivorship @DanaFarber in this discussion on UroToday > @Decipher_VCYT @Veracyte

0

3

4

1

3

5

Decipher by Veracyte

@Decipher_VCYT

7 years

GenomeDx’s @DecipherTest , GRID and Bladder Data to be Featured at the 2017 Genitourinary Cancers Symposium

0

5

4

Decipher by Veracyte

@Decipher_VCYT

1 year

A study of post-biopsy prostate cancer patients presented at #SUO2022 shows tumor volume was not associated with aggressive tumor biology (Decipher score) in Grade Group 1 disease, suggesting tumor volume may not be informative for active surveillance decisions in these patients.

Learn more about the study's findings:

secure-platform.com

0

2

5

Decipher by Veracyte

@Decipher_VCYT

11 months

The American Society of Clinical Oncology Annual Meeting is this weekend! If you're attending, be sure to check out these four abstracts featuring Veracyte's #Decipher GRID and Bladder! #ASCO #ASCO23 #OncTwitter

0

3

5

Decipher by Veracyte

@Decipher_VCYT

4 years

Two days until our free webinar featuring Dr. Ed Trabulsi and Dr. Robert Den! Register here:

0

2

4

Decipher by Veracyte

@Decipher_VCYT

3 years

Listen to part 3 of @UroToday ’s 3-part series! @DrSpratticus , @a_dalpra , @ashleyrossmdphd discuss two case studies in post-RP patients with rising PSA and how they use the @Veracyte Decipher prostate test to guide treatment decisions.

Clinical Case Discussions - "Rising PSA 18 Months Post RP and Timing of Radiotherapy" - Ashley...

Ashley Ross, MD, PhD, Alan Dal Pra, MD, and Daniel Spratt, MD, discuss two cases of patients each about 18 months post-prostatectomy with rising PSA, evaluating the timing to radiotherapy and the...

www.urotoday.com

0

5

Decipher by Veracyte

@Decipher_VCYT

1 year

If you're attending #AUA23 here in Chicago, be sure to check out these eight posters featuring @Veracyte 's #Decipher tests!

0

2

5

Decipher by Veracyte

@Decipher_VCYT

9 years

At #ASCO15 today? Come by poster 182 to see new @DecipherTest data in #bladdercancer - starting in 20 min in S Hall A http://t.co/BpZIpBPjUC

0

3

5

Decipher by Veracyte

@Decipher_VCYT

1 year

The #ACRO2023 Meeting ( @ACRORadOnc ) will be on March 15-18 in Lake Buena Vista, FL! If you plan to attend, stop by our booth & learn how @Veracyte 's #Decipher Prostate Genomic Classifier can help uncover underlying tumor biology & provide confidence in treatment planning.

1

3

5

Decipher by Veracyte

@Decipher_VCYT

7 years

The @Color Test is now available to physicians through @genomedx commercial channel:

2

10

5

Decipher by Veracyte

@Decipher_VCYT

3 years

We're excited to officially be part of the @Veracyte family. Together we will deliver comprehensive genomic cancer testing to physicians and patients and expand our reach into 7 of the top 10 cancers in the U.S. alone.

Veracyte Completes Acquisition of Decipher Biosciences | Veracyte, Inc.

The Investor Relations website contains information about Veracyte, Inc.'s business for stockholders, potential investors, and financial analysts.

investor.veracyte.com

0

4

5

Decipher by Veracyte

@Decipher_VCYT

4 years

In the midst of #COVID ー19, Decipher Biosciences is fully dedicated to our physicians and their patients, increasing our efforts to make Decipher available to all #ProstateCancer patients who may benefit from genomic profiling @NCCN #Decipher #biomarker

NCCN Guidelines Designate Decipher Prostate as "Recommended" for Men with Adverse Pathology after...

/PRNewswire/ -- Decipher Biosciences, a commercial-stage precision oncology company committed to improving patient care, initially focused on urologic cancers,...

www.prnewswire.com

0

3

5

Decipher by Veracyte

@Decipher_VCYT

6 years

GenomeDx Announces Inclusion of @DecipherTest in NCCN Guidelines for Prostate Cancer:

GenomeDx Announces Inclusion of Decipher Genomic Testing in NCCN Guidelines for Prostate Cancer

/PRNewswire/ -- GenomeDx Biosciences, a leader in the field of urologic cancer genomics, today announced that its Decipher® Prostate Biopsy and Decipher...

www.prnewswire.com

1

2

5

Decipher by Veracyte

@Decipher_VCYT

2 years

The American Urological Association 2022 Conference ( @AmerUrological ) begins this week on May 13-16! Join us at booth 1563 to learn about how @Veracyte 's Decipher Genomic Classifier can help men living with #ProstateCancer .

0

6

5

Decipher by Veracyte

@Decipher_VCYT

6 years

Please join us for a webinar with radiation oncologist, Robert Den, M.D., of Thomas Jefferson University, for a practical review of how to incorporate personalized prostate cancer genomics ( @DecipherTest ) into your practice. Register here:

0

3

Decipher by Veracyte

@Decipher_VCYT

10 years

@CMSGov Draft Coverage Decision to Reimburse @DecipherTest for Int & High Risk PCa: http://t.co/BttKnlKid6 @Davicioni @Kassoli1 @zaid_ha

0

3

5

Decipher by Veracyte

@Decipher_VCYT

2 years

PSA of ≥20 ng/mL can make an otherwise low risk prostate cancer be categorized as high risk. Patients in the heterogenous high-risk group can be better risk-stratified using genomics. @Veracyte 's #Decipher Prostate test can help w/ shared decision-making:

0

2

5

Decipher by Veracyte

@Decipher_VCYT

3 years

Dr. Sean McGuire of @MDAndersonNews calls the study a "hugely important milestone" as it provides the first validation of Decipher "as a correlative component of the large, well-designed, prospective, double-blind phase 3 trial NRG/RTOG 9601." #prostatecancer #genomics #GU21

JAMA Oncology

@JAMAOnc

3 years

Invited commentary about strength of evidence & clinical utility of genomic risk testing for prostate cancer argues new data on the 22-gene Decipher Genomic Classifier vaults it into range of being ready for broad clinical use

1

5

8

0

3

5

Decipher by Veracyte

@Decipher_VCYT

3 years

September is #ProstateCancer Awareness Month! Prostate cancer is the most common cancer among American men & the second highest cause of cancer-related deaths. Learn how the @Veracyte #Decipher Prostate Cancer Test can help stratify risk. #PCAM21

0

2

5